Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-center, Randomized, Double-blind, Methotrexate Controlled Study to Assess the Clinical Efficacy, Safety, and Tolerability of CH-1504 in Subjects With Active Rheumatoid Arthritis

NCT00658047 is registered in ClinicalTrials.gov with Chelsea Therapeutics as lead sponsor.

NCT NCT00658047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00658047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-center, Randomized, Double-blind, Methotrexate Controlled Study to Assess the Clinical Efficacy, Safety, and Tolerability of CH-1504 in Subjects With Active Rheumatoid Arthritis
Lead sponsor
Chelsea Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
June 30, 2009
Enrollment
201 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid